US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
US6849714B1
(en)
*
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
SI1180121T1
(en)
*
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6887470B1
(en)
*
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US20040266673A1
(en)
*
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US6447772B1
(en)
*
|
1999-10-01 |
2002-09-10 |
Klaire Laboratories, Inc. |
Compositions and methods relating to reduction of symptoms of autism
|
ES2311560T3
(es)
*
|
2000-12-07 |
2009-02-16 |
Eli Lilly And Company |
Proteinas de fusion glp-1.
|
BR0206919A
(pt)
|
2001-02-02 |
2004-07-06 |
Conjuchem Inc |
Derivados de fator de liberação de hormÈnio de crescimento de longa duração
|
AU2002233089B2
(en)
*
|
2001-02-16 |
2005-12-22 |
Conjuchem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
ES2242860T3
(es)
|
2001-05-31 |
2005-11-16 |
Conjuchem, Inc. |
Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US6642003B2
(en)
|
2001-08-02 |
2003-11-04 |
Cedars-Sinai Medical Center |
Human glucose-dependent insulin-secreting cell line
|
US20030226155A1
(en)
*
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US20070031440A1
(en)
*
|
2001-08-30 |
2007-02-08 |
Prior Christopher P |
Modified transferin-antibody fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
IL160289A0
(en)
*
|
2001-08-30 |
2004-07-25 |
Biorexis Pharmaceutical Corp |
Modified transferrin fusion proteins
|
PT1463751E
(pt)
*
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
AU2002364587A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2476468A1
(en)
*
|
2002-02-13 |
2003-08-21 |
Medbridge, Inc. |
Protein carrier system for therapeutic oligonucleotides
|
MXPA04008068A
(es)
*
|
2002-02-20 |
2004-11-26 |
Lilly Co Eli |
Metodo para administrar moleculas de glp-1.
|
US7141240B2
(en)
*
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
AU2003239478A1
(en)
*
|
2002-06-04 |
2003-12-22 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
EP1837031B1
(de)
*
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Methoden und Kompositionen um Diabetes zu behandeln
|
WO2004005342A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
DE60333306D1
(de)
*
|
2002-08-30 |
2010-08-19 |
Biorexis Pharmaceutical Corp |
Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
|
CA2500248C
(en)
*
|
2002-09-24 |
2013-03-19 |
Frontier Biotechnologies Co., Ltd. |
Peptide derivative fusion inhibitors of hiv infection
|
US7544657B2
(en)
*
|
2002-10-02 |
2009-06-09 |
Zealand Pharma A/S |
Stabilized Exendin-4 compounds
|
US20040229810A1
(en)
*
|
2002-10-22 |
2004-11-18 |
Antonio Cruz |
Gastrin compositions and formulations, and methods of use and preparation
|
US20040209803A1
(en)
*
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
NZ541365A
(en)
*
|
2002-12-27 |
2009-09-25 |
Diobex Inc |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US20070060512A1
(en)
*
|
2003-03-04 |
2007-03-15 |
Homayoun Sadeghi |
Dipeptidyl-peptidase protected protein
|
US20040242568A1
(en)
*
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
BRPI0408978B8
(pt)
*
|
2003-04-08 |
2021-07-27 |
Novo Nordisk As |
processos para regenerar uma fase estacionária cromatográfica
|
WO2004089985A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
EP3572106A1
(de)
|
2003-04-23 |
2019-11-27 |
Valeritas, Inc. |
Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
|
WO2004106299A2
(en)
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
AU2004251145C1
(en)
|
2003-06-12 |
2011-04-14 |
Eli Lilly And Company |
GLP-1 analog fusion proteins
|
ES2328579T3
(es)
*
|
2003-07-25 |
2009-11-16 |
Conjuchem Biotechnologies Inc. |
Derivados de insulina de larga duracion y procedimientos asociados.
|
CN1964989B
(zh)
*
|
2003-07-25 |
2012-02-01 |
康久化学生物技术公司 |
长效胰岛素衍生物及其方法
|
US7790736B2
(en)
*
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007512001A
(ja)
*
|
2003-08-28 |
2007-05-17 |
バイオレクシス ファーマシューティカル コーポレイション |
Epoミメティックペプチドおよび融合タンパク質
|
US20060205037A1
(en)
*
|
2003-08-28 |
2006-09-14 |
Homayoun Sadeghi |
Modified transferrin fusion proteins
|
EP1663289A2
(de)
*
|
2003-08-29 |
2006-06-07 |
Amylin Pharmaceuticals, Inc. |
Verfahren zur behandlung oder linderung von erkrankungen und störungen im zusammenhang mit ghrelin
|
US7790734B2
(en)
*
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7214190B1
(en)
|
2003-09-09 |
2007-05-08 |
Kitchener Clark Wilson |
Apparatus and method for noninvasive monitoring of analytes in body fluids
|
CN101665538A
(zh)
*
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
US20060286129A1
(en)
*
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
CA2554458A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN102134229B
(zh)
*
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
CN1956998B
(zh)
*
|
2004-04-23 |
2012-12-12 |
康久有限责任公司 |
用于纯化白蛋白结合物的方法
|
CN1318587C
(zh)
*
|
2004-04-30 |
2007-05-30 |
成都芝田生物工程有限公司 |
酰胺化Exendin-4多肽的重组制备方法
|
US9089636B2
(en)
|
2004-07-02 |
2015-07-28 |
Valeritas, Inc. |
Methods and devices for delivering GLP-1 and uses thereof
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
EP2330126B1
(de)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Exendin-4-Zusammensetzungen mit verlängerter Halbwertszeit
|
CN112618700A
(zh)
*
|
2004-11-12 |
2021-04-09 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
WO2006068978A2
(en)
*
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
US8716221B2
(en)
*
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
TWI376234B
(en)
|
2005-02-01 |
2012-11-11 |
Msd Oss Bv |
Conjugates of a polypeptide and an oligosaccharide
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US20090286723A1
(en)
*
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
RU2007134155A
(ru)
|
2005-03-18 |
2009-04-27 |
Ново Нордиск А/С (DK) |
Glp-1 соединения с увеличенным временем полужизни
|
US20070060529A1
(en)
*
|
2005-09-14 |
2007-03-15 |
Christopher Ronald J |
Administration of dipeptidyl peptidase inhibitors
|
KR101352588B1
(ko)
*
|
2005-09-14 |
2014-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
당뇨병 치료용 디펩티딜 펩티다아제 억제제
|
PL1942898T5
(pl)
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
|
CN102675221A
(zh)
*
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
WO2007051987A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Activotec Spp Limited |
Insulinotropic compounds and uses thereof
|
KR101329112B1
(ko)
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
CN101384623B
(zh)
*
|
2005-12-22 |
2013-07-24 |
常山凯捷健生物药物研发(河北)有限公司 |
白蛋白与治疗剂的预成型偶联物的制备方法
|
EP1816201A1
(de)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
|
CN101379075B
(zh)
*
|
2006-02-08 |
2013-05-15 |
隆萨股份公司 |
类胰高血糖素肽的合成
|
WO2007112368A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
CN101460216B
(zh)
|
2006-03-30 |
2013-06-19 |
瓦莱里塔斯公司 |
多筒式流体递送器械
|
KR101106510B1
(ko)
|
2006-05-30 |
2012-01-20 |
인타르시아 세라퓨틱스 인코포레이티드 |
투피스, 내부채널 삼투압 전달 시스템 유동 조절기
|
KR100886783B1
(ko)
|
2006-06-12 |
2009-03-04 |
성균관대학교산학협력단 |
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
|
EP2049567A2
(de)
|
2006-07-18 |
2009-04-22 |
Centocor, Inc. |
Menschliche glp-1-mimetikörper, zusammensetzungen, verfahren und anwendungen
|
ATE524493T1
(de)
*
|
2006-07-24 |
2011-09-15 |
Biorexis Pharmaceutical Corp |
Exendin-fusionsproteine
|
DK2049081T3
(da)
|
2006-08-09 |
2013-02-25 |
Intarcia Therapeutics Inc |
Osmotiske leveringssystemer og stempelarrangementer
|
GEP20125701B
(en)
*
|
2006-09-13 |
2012-12-10 |
Takeda Pharmaceuticals Co |
Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
|
TWI430806B
(zh)
*
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
用於投與長效降血糖藥劑之方法
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
US20090099074A1
(en)
*
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
JP2010530962A
(ja)
*
|
2007-06-12 |
2010-09-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
血漿においてタンパク質を検出する方法
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
US7960336B2
(en)
*
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
ES2672770T3
(es)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
EP2190873B1
(de)
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Verkürzte glp-1-derivate und ihre therapeutische verwendung
|
EP2190460B1
(de)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Mit a-b-c-d derivatisierte peptide und ihre therapeutische verwendung
|
EP2205624B1
(de)
*
|
2007-10-27 |
2016-09-07 |
Corden Pharma Colorado, Inc. |
Synthese eines insulinotropen peptids mithilfe von feststoff- und flüssigphasenkombinationsverfahren
|
US20090186819A1
(en)
*
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
EP2303313B1
(de)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendine zur senkung der cholesterin- und triglyceridwerte
|
AU2009260302B2
(en)
|
2008-06-17 |
2014-10-23 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
JP6108659B2
(ja)
|
2008-06-17 |
2017-04-05 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト
|
EP2307038A4
(de)
|
2008-06-27 |
2013-03-27 |
Univ Duke |
Elastinartige peptide umfassende therapeutische mittel
|
KR20110039348A
(ko)
|
2008-08-06 |
2011-04-15 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
BRPI0920209A2
(pt)
|
2008-10-15 |
2015-12-22 |
Angiochem Inc |
conjugados de agonistas de glp-1 e usos dos mesmos
|
KR101820024B1
(ko)
|
2008-10-17 |
2018-01-18 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린과 glp-1 효능제의 병용물
|
AU2009322043A1
(en)
|
2008-12-05 |
2011-07-07 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
SI2373681T1
(sl)
|
2008-12-10 |
2017-05-31 |
Glaxosmithkline Llc Corporation Service Company |
Farmacevtski sestavki albiglutida
|
US8513192B2
(en)
|
2009-01-22 |
2013-08-20 |
Novo Nordisk A/S |
Stable growth hormone compounds resistant to proteolytic degradation
|
US20120003695A1
(en)
|
2009-02-25 |
2012-01-05 |
Davidson Robert C |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
|
WO2010118384A2
(en)
|
2009-04-10 |
2010-10-14 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist compounds for estrogen-deficient mammals
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
CN102596993A
(zh)
*
|
2009-07-02 |
2012-07-18 |
安吉奥开米公司 |
多聚体肽结合物以及其应用
|
CN101987868B
(zh)
*
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
CN105963710A
(zh)
|
2009-08-06 |
2016-09-28 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
CN107638562B
(zh)
|
2009-09-28 |
2022-12-02 |
精达制药公司 |
基本稳态药物递送的快速建立和/或终止
|
CN102596259B
(zh)
*
|
2009-09-30 |
2015-03-11 |
国立大学法人京都大学 |
胰岛成像用分子探针及其使用
|
US20120264685A1
(en)
|
2009-10-22 |
2012-10-18 |
Rajesh Bahekar |
Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
|
ES2534191T3
(es)
|
2009-11-13 |
2015-04-20 |
Sanofi-Aventis Deutschland Gmbh |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
HUE037735T2
(hu)
|
2009-11-13 |
2018-09-28 |
Sanofi Aventis Deutschland |
DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
|
MX2012005912A
(es)
|
2009-11-23 |
2012-10-05 |
Amylin Pharmaceuticals Inc |
Conjugado de polipeptido.
|
RU2012134974A
(ru)
|
2010-01-22 |
2014-02-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированное соединение гормона роста
|
CN103002918B
(zh)
|
2010-01-22 |
2016-05-04 |
诺沃—诺迪斯克保健股份有限公司 |
体内功效延长的生长激素
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
MX2012009802A
(es)
|
2010-02-24 |
2012-09-12 |
Merck Sharp & Dohme |
Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
|
CA2792663A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
EP2555791B1
(de)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
|
US9089538B2
(en)
|
2010-04-27 |
2015-07-28 |
Zealand Pharma A/S |
Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
WO2011143208A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
EP2569000B1
(de)
|
2010-05-13 |
2017-09-27 |
Indiana University Research and Technology Corporation |
Glucagon-superfamilien-peptide mit nuklearhormon-rezeptoraktivität
|
BR112013004756B1
(pt)
|
2010-08-30 |
2020-04-28 |
Sanofi Aventis Deutschland |
uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
|
PL2651398T3
(pl)
|
2010-12-16 |
2018-05-30 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
SG10201600912SA
(en)
*
|
2011-03-04 |
2016-03-30 |
Intrexon Corp |
Vectors conditionally expressing protein
|
CN103619175B
(zh)
|
2011-04-12 |
2016-08-17 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
EP2723367B1
(de)
|
2011-06-22 |
2017-05-03 |
Indiana University Research and Technology Corporation |
Coagonisten des glucagon/glp-1 rezeptors
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプターコアゴニスト
|
KR101357117B1
(ko)
*
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013029279A1
(zh)
*
|
2011-09-03 |
2013-03-07 |
深圳市健元医药科技有限公司 |
新的glp-ⅰ类似物及其制备方法和用途
|
CN102286092B
(zh)
*
|
2011-09-14 |
2014-01-01 |
深圳翰宇药业股份有限公司 |
利拉鲁肽的固相合成方法
|
IN2014CN02448A
(de)
|
2011-09-23 |
2015-06-19 |
Novo Nordisk As |
|
JP6359972B2
(ja)
|
2011-11-03 |
2018-07-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体アゴニストペプチドガストリンコンジュゲート
|
WO2013112548A1
(en)
|
2012-01-23 |
2013-08-01 |
University Of South Florida |
Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
|
TR201903918T4
(tr)
|
2012-03-22 |
2019-04-22 |
Novo Nordisk As |
Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
|
HRP20231060T1
(hr)
|
2012-03-22 |
2023-12-22 |
Novo Nordisk A/S |
Pripravci peptida glp-1 i njihova priprava
|
WO2013163162A1
(en)
*
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
CA3062003C
(en)
|
2012-05-17 |
2022-01-11 |
Extend Biosciences, Inc. |
Vitamin d as a targeting group for therapeutic peptides
|
CN104487056A
(zh)
|
2012-06-20 |
2015-04-01 |
诺和诺德A/S(股份有限公司) |
包含肽和递送剂的片剂制剂
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
CA2877363A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
CN104662038B
(zh)
|
2012-07-23 |
2018-11-06 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
CN104870009B
(zh)
|
2012-12-21 |
2021-05-18 |
赛诺菲 |
官能化的毒蜥外泌肽-4衍生物
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
ES2771478T3
(es)
|
2013-02-18 |
2020-07-06 |
Vegenics Pty Ltd |
Moléculas de unión a ligando y usos de las mismas
|
CA2904332A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
CN104650212A
(zh)
*
|
2013-03-15 |
2015-05-27 |
深圳君圣泰生物技术有限公司 |
一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
|
CN104592380A
(zh)
*
|
2013-03-15 |
2015-05-06 |
深圳君圣泰生物技术有限公司 |
一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
|
WO2014161835A1
(en)
*
|
2013-04-03 |
2014-10-09 |
Sanofi |
Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
|
EP2981282B1
(de)
|
2013-04-05 |
2020-11-04 |
Novo Nordisk Health Care AG |
Wachstumshormonverbindungsformulierung
|
MX362275B
(es)
|
2013-04-18 |
2019-01-10 |
Novo Nordisk As |
Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
|
KR102569036B1
(ko)
|
2013-10-17 |
2023-08-23 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
US10131702B2
(en)
|
2013-11-06 |
2018-11-20 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
EP3080154B1
(de)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Duale glp-1/gip-rezeptoragonisten
|
EP3080152A1
(de)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Nicht-acylierte exendin-4-peptidanaloga
|
EP3080149A1
(de)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Duale glp-1-/glucagon-rezeptoragonisten
|
EP3082847A1
(de)
|
2013-12-20 |
2016-10-26 |
Indiana University Research and Technology Corporation |
Fusionspolypeptide aus lipidiertem inkretin-rezeptor-ligand und human-immunoglobulin-fc-region
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
US9895424B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
CN106536547A
(zh)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
用于医疗用途的glp‑1/胰高血糖素受体共激动剂
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
EP3206710B1
(de)
|
2014-09-24 |
2020-05-06 |
Indiana University Research & Technology Corporation |
Inkretininsulinkonjugate
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
EP3220961B1
(de)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutische vitamin-d-konjugate
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
RU2716985C2
(ru)
|
2014-10-29 |
2020-03-17 |
Зилэнд Фарма А/С |
Соединения-агонисты gip и способы
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
RU2735762C2
(ru)
|
2015-04-16 |
2020-11-06 |
Зилэнд Фарма А/С |
Ацилированный аналог глюкагона, его применение и способы получения
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
CA2989400A1
(en)
|
2015-06-15 |
2016-12-22 |
Angiochem Inc. |
Ang1005 for the treatment of leptomeningeal carcinomatosis
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|
CA3008392C
(en)
|
2015-12-17 |
2021-11-09 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
WO2017112889A1
(en)
|
2015-12-23 |
2017-06-29 |
The Johns Hopkins University |
Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
|
CA3020339C
(en)
|
2016-04-07 |
2022-05-03 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
BR112018073511A2
(pt)
|
2016-05-16 |
2019-03-26 |
Intarcia Therapeutics, Inc. |
polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CN108070030B
(zh)
*
|
2016-11-17 |
2023-06-23 |
江苏豪森药业集团有限公司 |
洛塞那肽及其类似物的制备方法
|
AU2017371516C1
(en)
|
2016-12-09 |
2021-09-02 |
Zealand Pharma A/S |
Acylated GLP-1/GLP-2 dual agonists
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
CN109503700A
(zh)
*
|
2017-09-14 |
2019-03-22 |
南京安吉生物科技有限公司 |
马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
|
US10905750B2
(en)
|
2017-11-10 |
2021-02-02 |
Donald J. Davidson |
GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
|
EP3746111B1
(de)
|
2018-02-02 |
2023-07-19 |
Novo Nordisk A/S |
Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
JP2022504596A
(ja)
|
2018-10-11 |
2022-01-13 |
インターシア セラピューティクス,インコーポレイティド |
ヒトアミリンアナログペプチド及び使用方法
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
CN110183531A
(zh)
*
|
2019-05-17 |
2019-08-30 |
河北常山生化药业股份有限公司 |
一种艾本那肽前体的制备方法
|
CN111333714A
(zh)
*
|
2020-03-05 |
2020-06-26 |
成都奥达生物科技有限公司 |
一种长效glp-1化合物
|
JP2023520989A
(ja)
*
|
2020-03-27 |
2023-05-23 |
エピバックス・インコーポレーテッド |
1型糖尿病の予防および治療に有用なtレジトープ構築物
|